| Literature DB >> 23031570 |
Safoora Ebadi1, Noureddin Nakhostin Ansari, Soofia Naghdi, Shohre Jalaei, Mirmostafa Sadat, Hosein Bagheri, Maurits W Vantulder, Nicholas Henschke, Ehsan Fallah.
Abstract
BACKGROUND: Non-specific chronic low back pain (NSCLBP) is one of the most common musculoskeletal disorders around the world including Iran. One of the most widely used modalities in the field of physiotherapy is therapeutic ultrasound (US). Despite its common use, there is still inconclusive evidence to support its effectiveness in patients with NSCLBP. The objective of this study was to evaluate the effect of continuous US compared with placebo US additional to exercise therapy for patients with NSCLBP.Entities:
Mesh:
Year: 2012 PMID: 23031570 PMCID: PMC3537701 DOI: 10.1186/1471-2474-13-192
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Figure 1Flow diagram of participation and withdrawals for patients in continuous ultrasound and placebo ultrasound groups.
Characteristics of patients with non specific chronic low back pain before treatment in continuous ultrasound and placebo ultrasound groups
| Age(years) | 31.4 | 12.3 | 37.4 | 11.9 | .09 |
| Onset since first episode(years) | 5.8 | 4.1 | 8.1 | 4.7 | .08 |
| BMI** | 24.4 | 4.1 | 25.3 | 3.5 | .39 |
| Sex | 25%female _ 75%male | 50%female _ 50%male | |||
* Ultrasound.
** Body Mass Index.
***p values are for baseline differences between the two groups. Significance level ≤ .05.
Mean and SD of primary and secondary outcome measures for continuous ultrasound and placebo ultrasound groups at baseline, after 10 treatment sessions, and after 1 month follow up
| FRI** | 40.8 (14.6) | 23.4 (6.9) | 22.8 (7.8) | 43.9 (16.9) | 31.1 (13.4) | 30.5 (11.9) | .49 |
| VAS** | 46.6 (17.7) | 26.6 (13.8) | 27.7 (14.4) | 49 (16) | 30.7 (13.1) | 25.5 (9.9) | .62 |
| Flexion ROM (millimeters) | 48.8 (19.4) | 52.4 (18.6) | 52.4 (19.60) | 57.4 (18.9) | 59.8 (17.9) | 57.5 (18.3) | .13 |
| Extension ROM (millimeters) | 19.4 (8.2) | 20.12 (8.5) | 21.7 (8.5) | 23.6 (9.6) | 24.1 (9.3) | 24.7 (9.6) | .11 |
| Endurance time(in seconds) | 111.5 (33.5) | 128.9 (30.2) | 128.3 (26.2) | 134.2 (27.1) | 140.3 (43.5) | 139.3 (45.8) | .01 |
| Median frequency slope of right muscles | |||||||
| Illiocostalis lumborum | -.24 (.17) | -.21 (.09) | -.19 (.07) | -.21 (.13) | -.20 (.06) | -.19 (.06) | .56 |
| Multifidus | -.26 (.15) | -.26 (.16) | -.24 (.13) | -.30 (.17) | -.25 (.05) | -.24 (.05) | .82 |
| Gluteus maximus | -.11 (.13) | -.09 (.10) | -.09 (.10) | -.13 (.13) | -.09 (.09) | -.09 (.1) | .65 |
| Biceps femoris | -.12 (.09) | -.12 (.08) | -.09 (.06) | -.11 (.07) | -.12 (.07) | -.09 (.05) | .83 |
| Median frequency slope of left muscles | |||||||
| Illiocostalis lumborum | -.18 (.11) | -.18 (.11) | -.16 (.09) | -.21 (.12) | -.19 (.07) | -.18 (.08) | .29 |
| Multifidus | -.24 (.14) | -.25 (.15) | -.25 (.15) | -.29 (.21) | -.24 (.10) | -.25 (.11) | .31 |
| Gluteus Maximus | -.06 (.04) | -.06 (.06) | -.08 (.05) | -.09 (.07) | -.08 (.05) | -.09 (.08) | .11 |
*US: Ultrasound.
**FRI: Functional Rating Index, VAS: Visual Analog Scale.
***p values are for baseline differences between the two groups at significance level ≤ .05.
Main effects of Time and Group and their interaction effect on primary and secondary outcome measures (CI=95%,) *
| 2 | 75.92 | <.001* | ||
| 1 | 3.90 | .004* | ||
| 2 | 1.03 | .31 | ||
| 2 | 80.11 | <0.001* | ||
| 1 | .00 | .48 | ||
| 2 | .514 | .98 | ||
| 2 | 3.47 | .09 | ||
| 1 | 3.16 | .02* | ||
| 2 | 1.48 | .23 | ||
| 2 | 1.53 | .11 | ||
| 1 | 4.12 | .03* | ||
| 2 | 1.61 | .21 | ||
| 2 | 0.63 | .43 | ||
| 1 | 3.05 | .05* | ||
| 2 | 1.99 | .17 | ||
| 2 | .39 | .53 | ||
| 1 | .01 | .93 | ||
| 2 | .52 | .41 | ||
| 2 | .06 | .16 | ||
| 1 | .16 | .69 | ||
| 2 | .52 | .48 | ||
| 2 | 3.41 | .73 | ||
| 1 | .02 | .89 | ||
| 2 | .52 | .47 | ||
| 2 | 5.38 | .86 | ||
| 1 | .02 | .79 | ||
| 2 | .05 | .82 | ||
| 2 | 3.65 | .06 | ||
| 1 | .87 | .35 | ||
| 2 | .38 | .54 | ||
| 2 | 1.49 | .23 | ||
| 1 | .14 | .71 | ||
| 2 | 1.22 | .27 | ||
| 2 | .98 | .33 | ||
| 1 | .95 | .33 | ||
| 2 | .86 | .36 |
*The effect of the US versus placebo US on outcome measures was analyzed using a Group (US and placebo US) × Time (Pre, Post, and follow-up) mixed model ANOVA at significance level ≤ .05.
**FRI: Functional Rating Index, VAS: Visual Analog Scale.